blood counts were inconsistent (very low-quality evidence). No serious adverse events were noted in the study. The Phase II dosefinding study of senicapoc (a Gardos channel blocker) compared to placebo showed that the high dose senicapoc showed significant improvement in change in hemoglobin level, the number and proportion of dense red blood cells, red blood cell count and indices and hematocrit value (very low-quality evidence). The results with low-dose senicapoc were similar to the high-dose senicapoc group but of lesser magnitude. There was no difference in the frequency of painful crises between the three groups (low-quality evidence). A subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control groups in the primary end point of painful crises.
Authors' conclusions
While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to evaluate the effectiveness of this therapy for people with sickle cell disease.
While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red blood cell survival (depending on dose), this did not lead to fewer painful crises.
Given this is no longer an active area of research, this review will no longer be regularly updated.
P L A I N L A N G U A G E S U M M A R Y

Drugs that aim to reduce the loss of water from red blood cells in people with sickle cell disease
Review question
We reviewed the evidence to assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.
Background
Sickle cell disease is an inherited condition that causes red blood cells to become sickle shaped when they lose water. This leads to a high risk of the blood vessels becoming blocked. Such blockages can cause pain, stroke and damage to organs. Recent therapies aim to stop the cells becoming sickle shaped by preventing them losing water.
Search date
The evidence is current to: 08 October 2018.
Study characteristics
The review included three studies with 524 people with sickle cell disease aged between 12 and 65 years of age. The intervention in one study was zinc sulphate and in two studies was senicapoc. Each study was compared to a placebo group (a substance which contains no medication). For each study people were selected for one treatment or the other randomly. The studies lasted from three months to 18 months.
Key results
The study with zinc sulphate showed that this drug may be able to reduce the number of sickle cell crises without causing toxic effects (low-quality evidence). There were 145 participants in this study and results showed a significant reduction in the total number of serious sickle-related crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15) (moderate-quality evidence). However, our analysis was limited since not all data were reported. Changes to red blood cell measurements and blood counts were not consistent (very low-quality evidence). No serious adverse events were noted in the study. The two studies with senicapoc demonstrated that this drug increases the red blood survival and has a role in preventing red blood cell dehydration in people with sickle cell disease (very low-quality evidence). The higher dose of the drug was more effective compared to the lower dose. But these changes in the red blood cells did not translate into positive clinical outcomes in terms of reduction in the number of sickle cell crises (low-quality evidence). Senicapoc had a favourable safety profile. More longer-term research is needed on these drugs and others that might prevent water loss in red blood cells.
Quality of the evidence
The quality of the evidence was mixed across outcomes. 
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Drugs to prevent red blood cell dehydration compared with placebo for sickle cell disease Patient or population: adults and children with sickle cell disease Settings: outpatients Intervention: drugs to prevent red blood cell dehydration (anti-sickling treatm ent) Comparison: placebo
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI)
No of Participants (studies)
Quality of the evidence (GRADE)
Comments
Assumed Num ber of sickle pain crises Follow-up: 12 weeks to 18 m onths There was no signif icant dif f erence in the rate of the sickle cell painf ul crises between the senicapoc and placebo groups in either study (Ataga 2008; Ataga 2011 ). There were 1.40 and 3.38 painf ul crises per participant in the zinc and control groups respectively (Gupta 1995) .
(3)
⊕⊕ low 1, 2 No data were available to enter into the analysis f or any of the three studies In the Gupta study, SDs could not be calculated f rom the data provided in the publication (Gupta 1995) . The 2011 Ataga study was term inated early and so there were f ew participants that completed treatm ent and duration of treatm ent varied (Ataga 2011) .
M D between the groups f or the num ber of other sickle-related com plications, M D -2.83 (95% CI -3.51 to -2.15) in f avour of the anti-sickling treatm ent (Gupta 1995) .
145
(1)
⊕⊕⊕ moderate 3
Test f or overall ef f ect: Z = 8.20 (P < 0.00001).
Red blood cell dehydration Follow-up: 12 weeks to 18 m onths High and low doses of senicapoc resulted in a signif icant decrease in the percentage of dense red blood cells com pared to the placebo (Ataga 2008) . There was a signif icant decrease in the M CV and M CH in the high-dose senicapoc group com pared to the placebo. The low-dose senicapoc caused a signif icant reduction in the M CH but not M CV when com pared to the placebo. There was no signif icant dif f erence in M CHC between the 2 intervention arm s and the placebo arm The Gupta paper reported signif icant im provem ents in laboratory param eters of red blood cell dehydration (hem oglobin, reticulocyte count, serum bilirubin and serum zinc level) in the intervention group (Gupta 1995) .
524
(3)
⊕ very low 4,5
There were no data available to enter into analysis and we have presented the results narratively Quality of lif e: Days of work lost per crisis Follow-up: 18 m onths M D between the groups f or the num ber of days of work lost per crisis, M D -1.50 (95% CI -2.24 to -0.76) in f avour of the anti-sickling treatm ent (Gupta 1995).
145
The study also reported m ean num ber of days in hospital per crisis to be slightly higher in the intervention group but this was not signif icant, M D 0.40 (95% CI -0.26 to 1.
06)
Num ber of other sicklerelated events: Follow-up: 12 weeks to 18 m onths
One study showed no dif f erence in other sickle-related events between anti-sickling treatm ent and placebo (Ataga 2008) .
90
In the rem aining studies, other events were events in the anti-sickling treatm ent groups were staphylococcal sepsis (n = 1), urinary tract inf ection (n = 1), m uscle strain (n = 1) and one case of bronchi-tis in the placebo group There were less episodes of inf ection reported in the intervention group com pared to the control group (Gupta 1995) .
* The basis f or the assumed risk (e.g. the m edian control group risk across studies) is provided in f ootnotes. The corresponding risk (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). CI: conf idence interval; M CH: m ean corpuscular hem oglobin; M CHC: m ean corpuscular hem oglobin concentration; M CV: m ean corpuscular volum e; M D: m ean dif f erence; RR: risk ratio; SD: standard deviation.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate quality: f urther research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate.
Low quality: f urther research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low quality: we are very uncertain about the estim ate.
1. Downgraded once due to low event rates causing im precision. 2. Downgraded once due to risk of bias f rom one study being term inated early and participants receiving treatm ent f or dif f erent durations. 3. Downgraded once due to risk of bias within the single study. Little inf orm ation was given regarding baseline characteristics, m aking it dif f icult to ascertain if the groups were suf f iciently sim ilar at the start of the study. 4. Downgraded twice due to risk of bias f rom one study being term inated early and participants receiving treatm ents f or dif f erent durations and one study giving little inf orm ation on baseline characteristics and num bers in each arm . 5. Downgraded once due to im precision as no data were available to analyse and only narrative results could be included.
B A C K G R O U N D
Description of the condition
Sickle cell disease is caused by the inheritance from both parents of a mutation in the beta-globin gene. The different types of the disease (e.g. SS, SC, SβThal) are caused by inheritance of different altered beta-globin genes, and this can be diagnosed with blood tests or genetic testing. It is so named because the red blood cells (erythrocytes) become distorted into unusual shapes when they give up the oxygen they carry, due to polymerisation of the abnormal hemoglobin within. This is accelerated by a cycle of red blood cell dehydration, which increases intracellular concentration of the sickle hemoglobin and hence polymerisation. One of the distinguishing features of sickle cell anemia is the presence of these dense, dehydrated red blood cells, which are easily destroyed and can mesh together to block blood vessels (vaso-occlusion). The disease is characterised by episodes of anemia, vaso-occlusive crises and organ damage, with symptoms which are unpredictable and differ between individuals (Serjeant 1992). It is most prevalent in populations originating from sub-Saharan Africa and parts of India; although population movement has made it a worldwide problem, with approximately 60,000 African-American and 10,000 British people with the disease (Davies 1997; Hickman 1999) . Clinical management centers around prophylaxis against infection, pain relief, hydration and periodic blood transfusion in many people to reduce the concentration of sickle cells in the blood stream. However, most treatment is symptomatic and, as a result, despite vastly improving care services, many people with the disease still die in childhood due to sudden bouts of infection, stroke, acute chest syndrome or splenic sequestration (Leikin 1989) . Clearly preventative measures would be preferable.
How the intervention might work
In an attempt to prevent the increased concentration of sickle hemoglobin (which causes polymerisation and deformation of the red blood cell), recent research has begun to target the physiological process leading to dehydration of the erythrocyte for therapeutic potential. Red blood cells are thought to undergo dehydration via two kinetically distinct pathways, a "fast track" process in reticulocytes (immature red blood cells), and a slow process involving mature erythrocytes. Dehydration via either pathway is due to the water loss accompanying primary loss from the cell of potassium and chloride ions. The major routes involved in sickle cell dehydration are the calcium-activated potassium channel (Gardos channel) operating in parallel with the conductive chloride pathway and the electroneutral potassium-chloride co-transporter(s) (Brugnara 1995) . Potential therapeutic approaches involve the use of drugs that reduce sickle cell dehydration via a block of these mechanisms.
The first route, and perhaps the most promising for therapy, is the Gardos channel. Upon deoxygenation of the sickle cell, potassium and water loss are induced as free intracellular calcium levels rise, possibly due to increased membrane permeability for calcium. The Gardos channel may also be positively modulated by vaso-active molecules such as endothelins (Rivera 2000) . Studies both in a mouse model for sickle cell disease (SAD mouse) and in humans have shown that this channel can be selectively inhibited by a group of drugs known as the imidazole antimycotics, including the anti-fungal agent clotrimazole (Brugnara 1993; Brugnara 1996; de Franceschi 1994) and a related compound Senicapoc (ICA-17043) (Stocker 2000) . Blocking of the Gardos channel resulted in increased potassium content and improved hydration of erythrocytes. Senicapoc (bis(4-fluorophenyl)phenyl acetamide) is a selective and potent blocker of the Gardos channel (Stocker 2003) . Dimethyl adipimate may also have an anti-sickling role via the Gardos channel (Gibson 2000) .
The role of the chloride conductance or exchange system in sickle cell dehydration has also been recently explored. In vitro, loss of potassium from deoxygenated human sickle cells could be limited by the reversible anion conductance inhibitor NS1652 (Bennekou 2000) . Further, the related compound, NS3623 (Bennekou 2001), which has a greater half-life in vivo, improved hydration in the SAD mouse. Potassium-chloride co-transport occurs via a different membrane protein, which is activated by acidity within the cell allowing loss of potassium and water. This is seen almost exclusively in reticulocytes. No drugs have been found to be useful in inhibiting the transporter, but it has been shown that divalent cations, such as magnesium ions (Brugnara 1987), can block the pathway, again protecting against dehydration. Magnesium preparations are currently marketed for treatment of constipation, boils, recurrence of seizures in eclampsia, renal failure and are recommended for emergency treatment of serious arrhythmias. Magnesium pidolate has been investigated in combination with hydroxyurea in a Phase I trial (Hankins 2008). Other strategies have also been suggested for reducing sickle red blood cell dehydration. These include a transmembrane sodiumpotassium pump mechanism which is partly responsible for increased ion permeability on deoxygenation. While this is thought to be a minor contributor to dehydration, dipyridamole has been shown to be a selective inhibitor of passive ion transfer and there is rationale, including the known effects on platelet and endothelial cell function, for testing its efficacy in sickle cell disease. Oxidative damage to the cell membrane, which can occur in sickle cell disease due to abnormal iron deposits, increases loss of potassium and water contributing to red blood cell dehydration (Brugnara 1995) . Oral iron chelators may help in this case, and antioxidants could also be useful (Gibson 1998). Nitric oxide, an endogenous compound which is thought to be an important regulator of smooth muscle tone and vasodilatation, is reduced in people with sickle cell disease (Qureshi 2000) . Preliminary studies in SAD mice have shown that it can reduce red blood cell dehydration (Adrie 2000), and oral supplementation with arginine, an amino acid which releases nitric oxide, (5% by weight) also induces a decrease in red blood cell density (Romero 2000) , via Gardos channel activity (Romero 2002) . Hydroxyurea, an anti-cancer compound proven to reduce sickle-related events (Charache 1995; Jones 2001) , improves the hydration status of sickle red blood cells (Ballas 1989), although it is not clear whether this is a direct effect, or a consequence of increased levels of fetal hemoglobin (HbF). In Brazil a local plant, Pfaffia paniculata, has been anecdotally reported to ameliorate clinical symptoms of sickle cell disease. The plant possibly contains a naturally occurring compound, which acts as a sodium ionophore. In vitro studies have shown increased erythrocyte deformability and sodium content of sickle red blood cells when treated with it, thus potentially rehydrating sickle cells (Ballas 2000). Piracetam (2-oxo-1-pyrrolidine acetamide), a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), works primarily in neurotransmission, but appears to have a beneficial effect on red blood cell rheology and thus able to reduce vaso-occlusive crises in people with sickle cell disease. The exact mechanism of this remains unclear. It does not appear to inhibit the Gardos channel as previously reported (Gini 1987; Stone 1988; Stuart 1990; Stuart 1992) . The use of piracetam for reducing the incidence of painful sickle cell disease crises is the subject of another Cochrane Review (Al Hajeri 2007).
Why it is important to do this review
All of these potential therapies look promising for reducing dehydration of red blood cells, and therefore ameliorating the symptoms of sickle cell disease. This review aims to bring together clinical trials in this area to establish the clinical value of this pharmaceutical approach. This is an update of previously published versions of the review (Nagalla 2010; Nagalla 2012; Riddington 2002; Singh 2007) .
O B J E C T I V E S
To determine whether pharmaceutical therapies designed to prevent red blood cell dehydration in sickle cell disease:
reduce mortality;
2. reduce sickle cell vaso-occlusive crises including episodes of pain and stroke;
3. reduce other complications associated with sickle cell disease, e.g. acute chest syndrome, infection, anemia, splenic sequestration, organ damage; 4. are associated with unacceptable adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized or quasi-randomized trials. Trials in which quasirandomized methods, such as alternation, are used were included if there was sufficient evidence that the treatment and control groups were similar at baseline.
Types of participants
People with known sickle cell disease (SS, SC, Sβ+ and Sβ0, proven by electrophoresis and sickle solubility test, with family studies or DNA tests as appropriate) of all ages and both sexes, in any setting.
Types of interventions
Pharmaceutical therapies designed to reduce red blood cell dehydration to prevent vaso-occlusive events in sickle cell disease compared to comparator interventions. Studies which included antisickling drugs for which the exact mechanism of action is not known were considered if there was some evidence that they act via the red blood cell membrane to prevent sickling. Piracetam was excluded since there is insufficient evidence that it acts primarily via the red blood cell membrane to improve red blood cell rheology. Hydroxyurea was excluded as the primary mechanism for this drug is through increasing foetal hemoglobin. Studies in which the intervention was given only to treat an existing sicklerelated event were excluded.
Types of outcome measures
While the interventions should, by definition, decrease dense sickled cells by reducing erythrocyte dehydration, such biochemical parameters were examined separately from clinical outcomes, to determine the effectiveness of the interventions in clinical practice. However, the hematological outcomes may also provide an indication of the efficacy, and potential effectiveness, of treatment, so these were also analyzed. 
Search methods for identification of studies
There were no restrictions regarding language or publication status.
Electronic searches
Relevant studies were identified from the Cystic Fibrosis & Genetic Disorders Review Group's Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)) [ 
Searching other resources
The bibliographic references of all retrieved literature were reviewed for additional reports of studies.
Data collection and analysis
Selection of studies
Two authors independently applied the inclusion criteria in order to select studies for inclusion in the review. If disagreement arose on the suitability of a study for inclusion in the review, the authors reached consensus by discussion.
Data extraction and management
Two authors independently extracted the data. Each author, using standard data acquisition forms, independently extracted data. If disagreement arose on the study quality, the authors reached a consensus by discussion. We planned to collect data at monthly time-frames. However, if data were reported at other time periods we planned to consider examining these as well.
Assessment of risk of bias in included studies
Two authors assessed the risk of bias of each study. In particular, authors examined details of the randomization method, allocation concealment, whether the study was blinded, whether intentionto-treat analyses were possible from the available data and if the number of participants lost to follow up or subsequently excluded from the study was recorded.
Measures of treatment effect
We recorded dichotomous outcomes e.g. life or death, as present or absent, whilst recording continuous data such as organ function tests as either mean change from baseline for each group or mean post treatment values and standard deviation (SD) for each group. We aimed to calculate a pooled estimate of the treatment effect for each outcome across studies, (for binary outcomes the odds of an outcome among treatment allocated participants to the corresponding odds among controls).
Unit of analysis issues
Cross-over trials will only be included in future versions of this review if we consider there to be a sufficient washout period between the treatment arms. We will analyze any data from such trials according to methods described by Elbourne (Elbourne 2002).
Dealing with missing data
We sought full reports from authors where studies have been published in abstract form, presented at meetings or reported to the co-authors. Where information was missing or unclear, we contacted the primary investigator. In order to allow an intention-to-treat analysis, we grouped data by allocated treatment groups, irrespective of later exclusion (regardless of cause) or loss to follow up.
Assessment of heterogeneity
We will test for heterogeneity between studies using a standard chi-squared test and I² statistic (Higgins 2003). We will use the following ranges to describe heterogeneity:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
Comprehensive searches were done by both the authors to minimize publication and reporting biases. We compared the 'Methods' section of the full published paper to the 'Results' section to ensure that all outcomes which were measured, were reported.
Data synthesis
We have used fixed-effect analysis with the data we have presented. If there is a high or moderate degree of heterogeneity between studies included in any future updates, we will consider using a random-effects analysis.
Subgroup analysis and investigation of heterogeneity
If we find heterogeneity between studies, examination of subgroups, such as age of participants, type of sickle cell disease or ethnicity, may help to explain the reasons for this. For future updates, where appropriate, we plan to perform subgroup analysis of different drugs or combinations of drugs to examine their relative risks and benefits.
Sensitivity analysis
If we include a sufficient number of studies where quasi-randomization methods are used, we will analyze this group separately.
Summary of findings tables
In a post hoc change, we have presented a summary of findings We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded the evidence by one level if we considered the limitation to be serious and by two levels if very serious.
R E S U L T S Description of studies
Results of the search
We identified 232 references and discarded 163 references as they were not relevant to the review. We further assessed 69 references (to 51 studies) and included three studies within the review (Ataga 2008; Ataga 2011; Gupta 1995) and excluded the remaining 48 studies.
Included studies Trial design
All three studies were described as double-blind, randomized placebo-controlled studies (Ataga 2008; Ataga 2011; Gupta 1995) . The Phase II Ataga study was a dose-finding study which compared a 10 mg dose of senicapoc to a 6 mg dose of senicapoc or to placebo. The trial was multicenter (19 medical centers) in the USA (Ataga 2008) . The study treated participants for 12 weeks (Ataga 2008) .The more recent senicapoc trial was a Phase III trial was conducted across 75 centers in 6 countries (Ataga 2011) . The participants were randomized to senicapoc (20 mg twice daily as a loading dose for 4 days followed by 10 mg daily) or placebo in a 1:1 fashion. The treatment phase consisted of 52 weeks followed by a follow-up period of 8 weeks (Ataga 2011) . The Gupta trial compared oral zinc (220 mg three times a day) to placebo. The trial was from a single center in India (Gupta 1995) . The Gupta study lasted for one and a half years; participants were seen weekly but data were analysed at the end of the follow-up period (Gupta 1995).
Participants
There were 524 participants with sickle cell disease included in the review. The Phase II senicapoc study randomized 90 participants aged between 18 to 60 years (Ataga 2008) . The Phase III senicapoc study randomized 297 participants between the ages of 16 and 65 years, but only the 289 participants in the modified intentto-treat group (participants who received at least one dose of the drug) were included in this review (Ataga 2011 ). In the remaining study, Gupta randomized 145 participants aged between 12 to 27 years (Gupta 1995).
In the Phase II senicapoc study, participants had at least one episode of sickle cell-related painful crisis four weeks prior to the study screening and participants taking hydroxyurea had to be on a stable dose of the drug for at least three months prior to their enrolment in the study (Ataga 2008) . In the Phase III senicapoc study, participants had at least two episodes of painful crisis within the preceding 12 months that required medical attention (Ataga 2011) . Participants on hydroxyurea in preceding 12 months were required to be on a stable dose of the drug prior to inclusion in the study (Ataga 2011) . Gupta excluded participants under five years of age or those who had a history of chronic persistent infection, evidence of organ failure, exposure to extreme temperatures or were taking other medication (Gupta 1995).
In the Phase II senicapoc study, all the participants who received at least one week of the drug and underwent the initial efficacy analysis were included in the modified intent-to-treat analysis. Eightyeight participants met this criteria and only two discontinued the study before the initial efficacy analysis (Ataga 2008) . In the Phase III senicapoc study 289 participants from the initial group of 297 were included in the modified intent-to-treat analysis based on participants who received at least one dose of the drug (Ataga 2011) . However, in the Gupta study, 15 participants out of the original 145 subsequently dropped out or were lost to follow-up, and these were not included in the analysis (Gupta 1995).
Interventions
The Phase II senicapoc study compared three groups: high-dose senicapoc (single 150 mg loading dose followed by 10 mg daily maintenance dose); or low-dose senicapoc (single 100 mg loading dose followed by 6 mg daily maintenance dose); or placebo (Ataga 2008) . The high-dose senicapoc group had 31 participants, the low-dose senicapoc and placebo groups had 29 and 30 participants assigned respectively. The Phase III senicapoc study stratified participants based on concomitant hydroxyurea therapy. In each of these groups participants were randomized to receive senicapoc (loading dose of 20 mg twice daily for four days followed by 10 mg daily) or placebo in a 1:1 fashion. Out of the 289 participants in the modified intent-to treat analysis, there were 163 participants in the hydroxyurea group and 126 in the non-hydroxyurea group. The hydroxyurea group had 84 participants receiving senicapoc and 79 participants on placebo. The non-hydroxyurea group had 61 senicapoc participants and 65 in the placebo group (Ataga 2011) . The third study randomized participants to receive either zinc sulphate (220 mg three times a day orally) or an identical placebo (Gupta 1995).
Outcomes measured
The Ataga Phase II study reported the effect of senicapoc on hemoglobin levels, red blood cell (RBC) indices, markers of hemolysis and painful crises. The primary end point of the study was the change in hemoglobin level with the secondary end points being changes in the number and proportion on the dense red blood cells (RBCs) and reticulocytes, lactate dehydrogenase, indirect bilirubin, RBC count, RBC indices, hematocrit and frequency of painful crises (Ataga 2008) . The primary end point in the Ataga Phase III was the frequency of sickle cell pain crises. TIme to the first, second and third acute painful crises was a secondary end point of the study (Ataga 2011) . The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte count, red blood cell count and dense erythrocytes were also measured. The Gupta study measured the number of sickle-related crises, and the number of days in hospital and working (or school) days lost for each crisis (Gupta 1995).
Excluded studies
Forty-eight studies were excluded. Reasons for exclusions were a lack of evidence that they were acting primarily on red blood cell dehydration pathways, or they were being used to treat a sicklerelated crisis, rather than preventing it, or the study was not randomized (see Characteristics of excluded studies table). Studies on piracetam were excluded since there is insufficient evidence that this drug acts primarily via the red blood cell membrane to improve red blood cell rheology (Alvim 2005; Piracetam Study 1998).
Risk of bias in included studies
Allocation
All three studies were judged to have a low risk of bias for the generation of the allocation sequence (Ataga 2008; Ataga 2011; Gupta 1995) . In both of the senicapoc studies an integrated voice response system was used in the centralized randomization protocol (Ataga 2008; Ataga 2011 ). In the zinc study, New Castle software was used to generate randomization (Gupta 1995) . Both the senicapoc studies and the zinc study did not report on allocation concealment and so all studies were judged to have an unclear risk of bias for this criteria (Ataga 2008; Ataga 2011; Gupta 1995) .
Blinding
Both the participants and treating physicians were blinded in all three studies and so were judged to have a low risk of bias (Ataga 2008; Ataga 2011; Gupta 1995) . Additionally, Ataga reported that the review committee were also blinded (Ataga 2008) .
Incomplete outcome data
In the senicapoc Phase II study, a modified intent-to-treat population was used in the efficacy analysis (Ataga 2008) . Two out of the the 90 participants dropped out prior to the initial assessment and so 88 participants were included as a part of the modified intentto-treat population. The safety analysis included all the 90 participants. A total of 10 participants did not complete the study; full reasons for this were given in the published paper and we therefore judged there to be a low risk of bias due to incomplete outcome data (Ataga 2008) . The Phase III senicapoc study was terminated early due to a lack of efficacy as determined by the unblinded Data Monitoring Committee (Ataga 2011) . The reasons for the Committee's decision were based on the fact that there was no significant improvement in the rate of sickle cell painful crises in participants treated with senicapoc compared to those on placebo (P = 0.38 versus P = 0.31 respectively) despite improvements in anemia and hemolysis. Moreover, comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not significantly different. The authors suggest that the increase in Hb level caused an increase in blood viscosity and offset the potential benefits of senicapoc with regards to painful crises. Furthermore, due to the early termination of the study, the duration that the drug was administered was different in the participants who stopped treatment early. Given these facts, we have not entered any data from this trial into the data tables and results are reported narratively. In the zinc study, a power calculation, which assumed 40% control event rate and 20% response, found that 130 participants were needed. Fifteen, of the 145 participants recruited, dropped out or were lost to follow-up, and these are not accounted for in the study publication (Gupta 1995). We therefore judge there to be an unclear risk of bias from reported outcome data for this study.
Selective reporting
In both the senicapoc studies and the zinc study, all outcomes stated in 'Methods' section were reported in the 'Results' section of the papers; therefore there is a low risk of bias for selective reporting for all studies (Ataga 2008; Ataga 2011; Gupta 1995) .
Other potential sources of bias
The participants in the Phase II senicapoc study were evenly matched in terms of their baseline characteristics between the three study arms (Ataga 2008) and this was also true for the Phase III senicapoc study (Ataga 2011) . There was no significant difference in the mean age, sex and the hospitalizations in the year prior to the enrolment in the study. We therefore judged both studies to have a low risk of bias for this domain. The zinc study gave little information regarding baseline characteristics, including disease severity and medical history of participants, making it difficult to ascertain if the groups were sufficiently similar at the start of the study (Gupta 1995) . Thus currently we judge there to be an unclear risk of bias for this study.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes 1. Number of deaths
No treatment related deaths were reported in the included studies (low-quality evidence) (Analysis 1.1) (Ataga 2008; Ataga 2011; Gupta 1995) .
Number of pain crises
No data were available to enter into the analysis for any of the three studies (low-quality evidence) (Gupta 1995; Ataga 2008; Ataga 2011). In the senicapoc Phase II study there were a total of 15 sickle cell crises, with the events being distributed equally between the placebo and the two intervention arms (five in each) (Ataga 2008) . So both the lower (6 mg) and higher doses (10 mg) of senicapoc did not help in the reduction of painful crises compared to placebo. The Phase III senicapoc study was terminated prematurely as it was unlikely to meet the primary endpoint (Ataga 2011) . There was no significant difference in the rate of the sickle cell painful crises between the senicapoc and placebo groups (0.38 versus 0.31, P = 0.054). There was no difference in the painful crises rate between the two treatment arms in the hydroxyurea group (0.39 versus 0.33, P = 0.483) but the rate of painful crises was significantly higher in the senicapoc group compared to the placebo group in participants not on hydroxyurea (0.37 versus 0.29, P = 0.037) (Ataga 2011) . The study included pain-only crises, acute chest syndrome, hepatic sequestration, priapism and stroke under the primary end point of sickle cell-related pain crises. Given that the study was terminated prematurely, there are very few participants who completed the treatment. The duration of the drug regimen was different in the participants who stopped treatment. Therefore we have not included any data from this trial in the data analysis table.
In the zinc study there were 91 vaso-occlusive crises in the intervention group, compared to 220 in the control group (Gupta 1995) . This amounts to, on average, 1.40 and 3.38 painful crises per participant in intervention and control groups respectively. Standard deviations cannot be calculated from the data provided in the publication, so we are attempting to contact the authors, and hope to provide this information in a future update.
Number of other serious sickle-related complications
In the Phase II senicapoc study, there were two episodes of pneumonia and one episode of bronchitis in the placebo group (Ataga 2008) . There was one episode of pneumonia in each of the intervention arms. There was a single episode of acute chest syndrome in the study and it occurred in the 6 mg (low-dose) senicapoc arm. There was one episode of aseptic necrosis of the bone in the lowdose senicapoc arm and one episode of deep venous thrombosis in the high-dose senicapoc arm. Furthermore, there was one episode of staphylococcal sepsis in the low-dose senicapoc group and one urinary tract infection in the high-dose senicapoc group. The only case of deep vein thrombosis was reported in the high-dose senicapoc group (Ataga 2008) . The Phase III senicapoc study included pain-only crises, acute chest syndrome, hepatic sequestration, priapism and stroke under the primary end point of sickle cell-related pain crises (Ataga 2011 ). In the zinc study, altogether there were 160 episodes of sicklerelated crises in the intervention group, and 344 in the control group (Gupta 1995) . Of these, vaso-occlusive crises accounted for 59% in the intervention group and 64% in the control group, mixed crises for 24% and 20% in the intervention and control groups respectively, 9% and 12% were hemolytic, 1% in each group sequestration and 1% in each group had aplastic crises. The mean number of all sickle-related crises in the intervention group was 2.46 (SD 1.04), compared to 5.29 (SD 2.58), in the control group. The MD between groups was -2.83 (95% CI -3.51 to -2.15), showing a statistically significant reduction in the participants treated with zinc (moderate-quality evidence) (Analysis 1.2) (Gupta 1995).
Secondary outcomes 1. Red blood cell dehydration
All three studies presented information on this outcome (very lowquality evidence) (Gupta 1995; Ataga 2008; Ataga 2011) . Both the high and low doses of senicapoc resulted in a significant decrease in the percentage of dense red blood cells compared to the placebo (Ataga 2008) . The magnitude of decrease was higher with the 10 mg senicapoc compared to the 6 mg senicapoc. There was a significant decrease in the MCV and mean corpuscular hemoglobin (MCH) in the high-dose senicapoc group compared to the placebo. The low-dose senicapoc caused a significant reduction in the MCH but not MCV when compared to the placebo. There was no significant difference in MCHC between the two intervention arms and the placebo arm. The biochemical markers of hemolysis like lactate dehydrogenase and indirect bilirubin were significantly lower in the senicapoc groups compared to the placebo group. The magnitude of the change was dependent on the dose of senicapoc. The findings seen in the Phase II senicapoc study were confirmed in the Phase III study where senicapoc was compared to a placebo (Ataga 2011) . The Gupta paper reported significant improvements in laboratory parameters of red blood cell dehydration (hemoglobin, reticulocyte count, serum bilirubin and serum zinc level) in the intervention group (Gupta 1995).
Full blood count
The senicapoc study demonstrated an increase in the hemoglobin level by 0.68 gm/dL in the high-dose senicapoc group compared to the 0.01 gm/dL increase in the placebo group (P < 0.001) (Ataga 2008) . There was no significant change in the hemoglobin level when 6 mg of senicapoc was compared to the placebo. There was significant increase in the RBC count with senicapoc compared to the placebo in a dose-dependent manner. Both the high and low doses of senicapoc resulted in a significant decrease in the percentage and absolute number of reticulocytes (Ataga 2008) . The above findings were confirmed in the Phase III senicapoc study. There was no significant change in the HbF levels (Ataga 2011) . Gupta reported that participants in the intervention group had a mean hemoglobin level of 7.9 g/dL compared to 6.8 g/dL in the control group (P < 0.01) (Gupta 1995). Other outcomes were not reported, and SDs were not given. Again, the authors will be contacted to clarify this information.
Quality of life measures
These measures were not assessed in the Phase II study of senicapoc (Ataga 2008) .
In the Phase III senicapoc study there was no difference in the FACIT-Fatigue scores between the two treatment arms irrespective of the hydroxyurea stratification. Similarly, there was no difference in the number of participants transfused, the number of transfusions or units per participant. The participants on senicapoc spent more days in the hospital compared to those on placebo (Ataga 2011) .
Gupta reported the mean length of hospital stay per crisis in the intervention and control groups respectively was 4.3 and 3.9 days, MD 0.40 (95% CI -0.28 to 1.06), with no significant difference (Analysis 1.3) (Gupta 1995). Days of work lost per crisis were 3.4 in the zinc group and 4.9 in the control group. Although there is a significant reduction in the number of work days lost in the zinc group, MD -1.50 (95% CI -2.24 to -0.76), on average hospital stay was longer in this group (moderate-quality evidence) (Analysis 1.3).
Other sickle-related events
In the Phase II senicapoc study (low-quality evidence), there was one episode of staphylococcal sepsis in the low-dose senicapoc group and one urinary tract infection in the high-dose senicapoc group (Ataga 2008) . There was one report of muscle strain in the high-dose senicapoc group and once case of bronchitis in the placebo group (Ataga 2008) .
In the Phase III senicapoc study there was no significant difference in other sickle cell-related events (pneumonia, asthma, fever, catheter-related infections) between the senicapoc and the placebo groups (Ataga 2011 ). In the zinc study, there were 108 episodes of infection reported in the intervention group compared to 204 in the control group (Gupta 1995).
Adverse drug reactions
In the Phase II senicapoc study three participants discontinued the study due to adverse events (Ataga 2008) . One of the participants in the low-dose senicapoc group had dyspnoea and weakness and two in the high-dose senicapoc group had acute chest syndrome and painful crises. Diarrhea and nausea of mild to moderate intensity were more common in the senicapoc groups compared to the placebo group. Nausea and urinary tract infections were significantly higher in the senicapoc-treated participants compared to placebo in the Phase III senicapoc study. All other adverse events were similar between the two treatment groups (Ataga 2011) . The Gupta study states that zinc was well-tolerated with no significant toxicity throughout the study, although it was unclear which potential toxic effects were monitored (Gupta 1995).
D I S C U S S I O N
Zinc deficiency in sickle cell disease has been shown in observational studies to correlate with disease severity (Gupta 1987; Karayalcin 1974) . Laboratory studies have shown that zinc can improve the sickle cell membrane status and antagonise intracellular calcium, and could therefore affect red blood cell dehydration (Bennekou 2001) . The Gupta study included in this review showed a significant reduction in the number of sickle-related events in one and a half years of use in people treated with zinc sulphate (moderate-quality evidence) (Gupta 1995). However, lack of data in the publication makes it difficult to analyse the effect on other outcomes, on painful crisis frequency in particular (lowquality evidence). In addition, changes to hematological indices, which could be used as biomarkers of RBC sickling, were inconclusive (very low-quality evidence). Further research is required to evaluate the effect of zinc on the basic mechanisms of sickle cell disease. Previous studies using zinc also suggest a benefit for other problems in sickle cell disease, including leg ulcers (Serjeant 1970) , growth (Zemel 2001), infection (Prasad 1999) and androgen deficiency in male participants (Prasad 1981) . However, these studies were not included in the review since they do not consider prevention of vaso-occlusive crises.
Senicapoc (ICA-17043) is a selective and potent blocker of the Gardos channel in the RBC (Stocker 2003) . The effect of this drug on the markers of hemolysis and hemoglobin level was evaluated in a 12-week, Phase II randomized double-blind study in people with sickle cell disease (Ataga 2008) . The findings of this study suggested an increase in the lifespan of the sickle red blood cells (very low-quality evidence), but there was no difference in the incidence of painful crises (low-quality evidence). A subsequent Phase III study was terminated early due to the lack of improvement in the vaso-occlusive pain crisis in people with sickle cell disease (Ataga 2011) .
A number of other studies did not satisfy the inclusion criteria, but are still relevant to this review. Cetiedil citrate is believed to act at the Gardos channel, antagonising the calcium-mediated potassium efflux from RBCs, thus affecting red blood cell hydration and preventing sickling. In two randomized controlled trials investigating this treatment of sickle pain crises, both found it to limit the duration of a pain crisis and reduce the number of sites of pain compared to placebo (Benjamin 1986; Cabannes 1983) . No studies have tested its use in preventing sickle crises.
Piracetam improves red blood cell rheology; however, the exact mechanism of this on the red blood cell membrane is unclear. It was initially believed to inhibit the Gardos channel, but later studies disproved this theory (Stone 1988; Stuart 1992) . It has been shown in one randomized controlled trial to decrease the number of pain crises (Piracetam Study 1998) and in another to have no effect in preventing pain crises (Alvim 2005) . For further information, please see the relevant Cochrane Review (Al Hajeri 2007).
Magnesium is known to inhibit the potassium-chlorine ion pump, and observational studies have shown benefits in sickle cell disease.
Sodium cromoglicolate can stabilise erythrocyte membranes by blocking chlorine or calcium channels. In an ex vivo study, two groups of nine children were given sodium cromoglicolate either by the nasal route or inhalation (Toppet 2000) . The percentage of sickled cells in the blood of all children significantly decreased, regardless of which group they were assigned to. Further studies are now needed to test the clinical benefit of this agent.
Diltiazem also proved useful in a pilot study which measured sickle pain intensity and duration and various hematological parameters (Rubio 1992) . It is a calcium channel blocker and may impact on red blood cell hydration.
It was been hypothesised that hydroxyurea may increase intrinsic levels of nitric oxide, and this may affect red blood cell hydration. Effectiveness of hydroxyurea is considered in a different Cochrane Review (Jones 2001) .
Zinc sulphate appears to be of benefit to people with sickle cell disease (Gupta 1995).
However, further research in the form of large well-designed randomized controlled trials is required to fully elucidate the true value in sickle cell disease of drugs which aim to prevent red blood cell dehydration.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
There is low-quality evidence that zinc sulphate is associated with a reduction in pain crises, and also with reductions in other sickle cell-related crises. This was despite the treatment not being associated with an improvement in any of the hematological outcomes.
While these results are encouraging, widespread introduction of this agent in the management of people with sickle cell disease is not indicated at present. Senicapoc clearly improves the red blood cell survival in a dosedependent manner (very low-quality evidence). But the improvement in the laboratory measures did not translate into clinical benefits. There was no reduction in the incidence of sickle cell crises with the use of senicapoc (low-quality evidence). Therefore, currently this drug cannot be used in clinical practice for the prevention of vaso-occlusive crises.
Implications for research
More studies are needed to evaluate the effect of zinc sulphate and of piracetam on the basic mechanisms of sickle cell disease. Further multicenter randomized controlled trials of zinc sulphate in people with sickle cell disease should be conducted. To investigate whether the findings previously reported are consistent and sustained, these future studies should be larger and longer term than the one reported in this review. Senicapoc improved red blood cell survival and decreased hemolysis. Further studies are needed to ascertain if this drug will be beneficial in some of the other complications of sickle cell disease such as pulmonary hypertension.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ataga 2008
Methods
Phase II, randomized, double-blind, placebo-controlled study. There was a screening phase and a 12-week treatment phase Participants 90 sickle cell participants were recruited at 19 medical centers in the USA. The participants were adults aged between 18 and 60 years with at least one episode of sickle cellrelated painful crisis 4 weeks prior to the study screening
Interventions
Participants were randomized to either: 1. high-dose senicapoc: a single 150 mg senicapoc loading dose followed by 10 mg daily maintenance dose; 2. low-dose senicapoc: a single 100 mg senicapoc loading dose followed by 6 mg daily maintenance dose; or 3. placebo.
Outcomes
Efficacy, safety, pharmacokinetic, and pharmacodynamic measures were obtained on day 1 of study, end of week 1 and every 2 weeks until the end of treatment phase Methods Phase III randomized, double-blind, placebo-controlled, parallel group study. There was a screening phase, a 52-week treatment phase, and a follow-up evaluation 8 weeks after the end of the study Participants 297 participants were recruited from 75 centers in the USA, Jamaica, Brazil, France, Trinidad and the UK. Participants aged between 16 and 65 years and had at least 2 episodes of painful crisis within the preceding 12 months that required medical attention were included. Participants on hydroxyurea in preceding 12 months were required to be on a stable dose of the drug prior to inclusion in the study
Notes
Risk of bias
Interventions
Participants were randomized to receive (in a 1:1 fashion): 1. senicapoc (loading dose of 20 mg twice daily for 4 days followed by 10 mg daily); or 2. placebo
Outcomes
The primary end point was the frequency of sickle cell pain crises. TIme to the first second and third acute painful crises was a secondary end point of the study (Ataga 2011) . The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte count, red blood cell count and dense erythrocytes was also measured. Quality of life measures were also included Notes 
Risk of bias
D A T A A N D A N A L Y S E S
(Continued)
One trial previously included in this review has been removed (Piracetam Study 1998) . The piracetam trial was excluded since the current authors believe there is insufficient evidence that it acts primarily via the red cell membrane to improve red cell rheology.
The search of the Group's Haemoglobinopathies Trials Register in November 2006 identified trials possibly eligible for inclusion. Two references were to already excluded studies and these references have been added to the appropriate study IDs (Adams-Graves 1997; Orringer 1991). One reference has been added to Excluded studies (Alvim 2005).
June 2004
New search has been performed The search of the Group's trials register identified eight new references, however, none were found to be eligible for inclusion in the review Five references to three newly identified studies have been excluded. Details of these studies can be found in the Excluded studies section of the review (Adams-Graves 1997; Al-Jam 'a 1999; Godeau 2003; Jacobson 1997; Pace 2003) . Three references identified were to two already excluded studies (Ataga 2002; Wambebe 2001) . These additional references have been added to the appropriate study IDs 1 July 2003 New search has been performed Five new studies have been identified for inclusion within the Excluded studies section of this review.
C O N T R I B U T I O N S O F A U T H O R S
Review from Issue 4, 2009
Dr Singh has stepped down from the review team and Dr Nagalla is now the lead author for this review. Together with Dr Ballas, Dr Nagalla has updated this review and acts as guarantor for this and subsequent versions of the review. 
